108 related articles for article (PubMed ID: 19357424)
1. Daily trimethoprim-sulfamethoxazole prophylaxis rapidly induces corresponding resistance among intestinal Escherichia coli of HIV-infected adults in Kenya.
Chiller TM; Polyak CS; Brooks JT; Williamson J; Ochieng B; Shi YP; Ouma P; Greene C; Hamel M; Vulule J; Bopp C; Slutsker L; Mintz E
J Int Assoc Physicians AIDS Care (Chic); 2009; 8(3):165-9. PubMed ID: 19357424
[TBL] [Abstract][Full Text] [Related]
2. Does cotrimoxazole prophylaxis for the prevention of HIV-associated opportunistic infections select for resistant pathogens in Kenyan adults?
Hamel MJ; Greene C; Chiller T; Ouma P; Polyak C; Otieno K; Williamson J; Shi YP; Feikin DR; Marston B; Brooks JT; Poe A; Zhou Z; Ochieng B; Mintz E; Slutsker L
Am J Trop Med Hyg; 2008 Sep; 79(3):320-30. PubMed ID: 18784222
[TBL] [Abstract][Full Text] [Related]
3. Comparison of atovaquone and azithromycin with trimethoprim-sulfamethoxazole for the prevention of serious bacterial infections in children with HIV infection.
Hughes WT; Dankner WM; Yogev R; Huang S; Paul ME; Flores MA; Kline MW; Wei LJ;
Clin Infect Dis; 2005 Jan; 40(1):136-45. PubMed ID: 15614703
[TBL] [Abstract][Full Text] [Related]
4. Multidrug-resistant Escherichia coli clonal groups causing community-acquired pyelonephritis.
Manges AR; Dietrich PS; Riley LW
Clin Infect Dis; 2004 Feb; 38(3):329-34. PubMed ID: 14727201
[TBL] [Abstract][Full Text] [Related]
5. Prophylaxis with trimethoprim-sulfamethoxazole for human immunodeficiency virus-infected patients: impact on risk for infectious diseases.
Dworkin MS; Williamson J; Jones JL; Kaplan JE;
Clin Infect Dis; 2001 Aug; 33(3):393-8. PubMed ID: 11438910
[TBL] [Abstract][Full Text] [Related]
6. Emergence of trimethoprim-sulfamethoxazole resistance in the AIDS era.
Martin JN; Rose DA; Hadley WK; Perdreau-Remington F; Lam PK; Gerberding JL
J Infect Dis; 1999 Dec; 180(6):1809-18. PubMed ID: 10558935
[TBL] [Abstract][Full Text] [Related]
7. Etiologies and manifestations of persistent diarrhea in adults with HIV-1 infection: a case-control study in Lima, Peru.
Cárcamo C; Hooton T; Wener MH; Weiss NS; Gilman R; Arevalo J; Carrasco J; Seas C; Caballero M; Holmes KK
J Infect Dis; 2005 Jan; 191(1):11-9. PubMed ID: 15592997
[TBL] [Abstract][Full Text] [Related]
8. Multistate evaluation of invasive pneumococcal diseases in adults with human immunodeficiency virus infection: serotype and antimicrobial resistance patterns in the United States.
Fry AM; Facklam RR; Whitney CG; Plikaytis BD; Schuchat A
J Infect Dis; 2003 Sep; 188(5):643-52. PubMed ID: 12934179
[TBL] [Abstract][Full Text] [Related]
9. Discontinuing prophylaxis against Pneumocystis carinii pneumonia.
Bender MA; Sax PE
N Engl J Med; 2001 May; 344(21):1639; author reply 1640-1. PubMed ID: 11374364
[No Abstract] [Full Text] [Related]
10. Discontinuing prophylaxis against Pneumocystis carinii pneumonia.
Le Moal G; Breux JP; Roblot F
N Engl J Med; 2001 May; 344(21):1639-41. PubMed ID: 11374363
[No Abstract] [Full Text] [Related]
11. Urinary infections due to multi-drug-resistant Escherichia coli among persons with HIV disease at a tertiary AIDS care centre in South India.
Vignesh R; Shankar EM; Murugavel KG; Kumarasamy N; Sekar R; Irene P; Solomon S; Balakrishnan P
Nephron Clin Pract; 2008; 110(1):c55-7. PubMed ID: 18724067
[TBL] [Abstract][Full Text] [Related]
12. Prevalence and predictors of trimethoprim-sulfamethoxazole resistance among uropathogenic Escherichia coli isolates in Michigan.
Brown PD; Freeman A; Foxman B
Clin Infect Dis; 2002 Apr; 34(8):1061-6. PubMed ID: 11914994
[TBL] [Abstract][Full Text] [Related]
13. Clonal groups and the spread of resistance to trimethoprim-sulfamethoxazole in uropathogenic Escherichia coli.
France AM; Kugeler KM; Freeman A; Zalewski CA; Blahna M; Zhang L; Marrs CF; Foxman B
Clin Infect Dis; 2005 Apr; 40(8):1101-7. PubMed ID: 15791508
[TBL] [Abstract][Full Text] [Related]
14. Co-trimoxazole administered for Pneumocystis carinii pneumonia prophylaxis does not interfere with saquinavir pharmacokinetics.
Maserati R; Villani P; Cocchi L; Regazzi MB
AIDS; 1998 May; 12(7):815-6. PubMed ID: 9619815
[No Abstract] [Full Text] [Related]
15. Cotrimoxazole prophylaxis for HIV-positive TB patients in developing countries.
Zachariah R; Massaquoi M
Trop Doct; 2006 Apr; 36(2):79-82. PubMed ID: 16611438
[TBL] [Abstract][Full Text] [Related]
16. Balancing individual benefit against public health risk: the impact of cotrimoxazole prophylaxis in HIV-infected patients on antimicrobial resistance.
Hamer DH; Gill CJ
Am J Trop Med Hyg; 2008 Sep; 79(3):299-300. PubMed ID: 18784218
[No Abstract] [Full Text] [Related]
17. A randomized trial of the discontinuation of primary and secondary prophylaxis against Pneumocystis carinii pneumonia after highly active antiretroviral therapy in patients with HIV infection. Grupo de Estudio del SIDA 04/98.
Lopez Bernaldo de Quiros JC; Miro JM; Peña JM; Podzamczer D; Alberdi JC; Martínez E; Cosin J; Claramonte X; Gonzalez J; Domingo P; Casado JL; Ribera E;
N Engl J Med; 2001 Jan; 344(3):159-67. PubMed ID: 11172138
[TBL] [Abstract][Full Text] [Related]
18. Trimethoprim-sulfamethoxazole (TMP-SMZ) dose escalation versus direct rechallenge for Pneumocystis Carinii pneumonia prophylaxis in human immunodeficiency virus-infected patients with previous adverse reaction to TMP-SMZ.
Leoung GS; Stanford JF; Giordano MF; Stein A; Torres RA; Giffen CA; Wesley M; Sarracco T; Cooper EC; Dratter V; Smith JJ; Frost KR;
J Infect Dis; 2001 Oct; 184(8):992-7. PubMed ID: 11574913
[TBL] [Abstract][Full Text] [Related]
19. Discontinuation of primary prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus type I-infected patients: the changes in opportunistic prophylaxis study.
Mussini C; Pezzotti P; Govoni A; Borghi V; Antinori A; d'Arminio Monforte A; De Luca A; Mongiardo N; Cerri MC; Chiodo F; Concia E; Bonazzi L; Moroni M; Ortona L; Esposito R; Cossarizza A; De Rienzo B
J Infect Dis; 2000 May; 181(5):1635-42. PubMed ID: 10823763
[TBL] [Abstract][Full Text] [Related]
20. Provisional WHO/UNAIDS recommendations on the use of contrimoxazole prophylaxis in adults and children living with HIV/AIDS in Africa.
;
Afr Health Sci; 2001 Aug; 1(1):30-1. PubMed ID: 12833907
[No Abstract] [Full Text] [Related]
[Next] [New Search]
